Clinical data | |
---|---|
Trade names | Felbatol |
AHFS/Drugs.com | Monograph |
MedlinePlus | a606011 |
Routes of administration | By mouth (tablets, oral suspension) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | >90% |
Metabolism | Hepatic |
Elimination half-life | 20–23 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.042.714 |
Chemical and physical data | |
Formula | C11H14N2O4 |
Molar mass | 238.243 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Felbamate (marketed under the brand name Felbatol by MedPointe) is an anticonvulsant[2] used in the treatment of epilepsy. It is used to treat partial seizures[3][4] (with and without generalization) in adults and partial and generalized seizures associated with Lennox–Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drug's usage to severe refractory epilepsy.